Legacy Healthcare's Cinainu Receives FDA Breakthrough Therapy Designation for Alopecia Areata in Adults, Adolescents and Children Aged 2 Years and Older
RegulatoryCinainuPositive
AI Analysis
Summary
Legacy Healthcare announced that the FDA has granted Breakthrough Therapy Designation to Cinainu for alopecia areata in adults, adolescents, and children aged 2 years and older. This designation expedites the development and review process for the novel botanical prescription drug.
Outcome Details
FDA granted Breakthrough Therapy Designation for Cinainu
Importance:8/10
Sentiment:
0.80
FDABreakthrough Therapy DesignationAlopecia Areatadermatologybotanical drug
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on October 13, 2026 6:10 PM